Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ROIV
SellHot AirRoivant Sciences Ltd. · Healthcare · United Kingdom · $25.1B · Avg Vol: $310M/d
COMPANY DESCRIPTION
Roivant Sciences Ltd. is a biopharmaceutical company focused on accelerating the development and commercialization of novel medicines by creating 'Vants' – specialized subsidiary companies each focused on a single therapeutic candidate. This unique 'Vant' model aims to de-risk and expedite drug development by focusing dedicated teams and capital on promising assets, fostering entrepreneurial efficiency. Roivant is an asset-centric biopharma holding company, aiming to reduce drug development costs and timelines through a decentralized structure.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 31.5M | 32.7M | 29.1M | 8.3M | -36.0% | 7.5M | 51.0M | 396.5M | 592.9% |
| EPS | — | -1.42 | 5.23 | -0.24 | -0.43 | — | -0.47 | — | — | — |
| Shares | — | 760.1M | 806.7M | 695.9M | 720.4M | -5.2% | 722.3M | — | — | — |
| Debt | 170.3M | 481.4M | 54.0M | 100.2M | 107.4M | -8.8% | 107.2M | — | — | — |
| Equity | — | 1.2B | 6.0B | 4.7B | 4.5B | 57.5% | — | — | — | — |
| Op CF | — | -843.4M | -765.3M | -839.5M | -750.3M | — | -816.5M | — | — | — |
| Inv CF | — | -44.3M | 5.2B | -1.8B | -682.3M | — | — | — | — | — |
| Fin CF | — | 499.5M | 419.4M | -1.2B | 134.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ROIV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd.(you) | $25.1B | 21 | Sell |
| IMCR | Immunocore Holdings plc | $1.9B | 17 | Strong Sell |
| ONT.L | Oxford Nanopore Technologies plc | $2.3B | 33 | Sell |
| SLN | Silence Therapeutics plc | $834M | 25 | Sell |
| OXB.L | Oxford Biomedica plc | $859M | 14 | Strong Sell |
| AUTL | Autolus Therapeutics plc | $623M | 30 | Sell |
| GNS.L | Genus plc | $2.1B | 62 | Hold |
| AVCT.L | Avacta Group Plc | $433M | 10 | Strong Sell |
| BCYC | Bicycle Therapeutics plc | $294M | 10 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 55.3%